[5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer].
OBJECTIVE
We studied prophylactic intravesical instillation of mitomycin C (MMC) and pirarubicin (THP) following transurethral resection of bladder tumor (TUR-Bt) for superficial bladder cancer.


METHODS
Forty-six evaluable patients were administered intravesically 20 mg of MMC dissolved in 20 ml saline on day 1 and 20 mg of THP dissolved 20 ml 5% dextrose on day 2. The patients were followed up by cystscopy and urinary cytology. Intravesical instillations were performed once a month and continued for 5 years.


RESULTS
The non-recurrence rates at 1, 3 and 5 years were 88.8%, 79.5% and 67.0%, respectively. No significant differences were observed between grade 1-2 and 3, male and female, and solitary and multiple tumors. Although the side effects were relatively mild, 6 patients were stopped intravesical instillation.


CONCLUSIONS
Because non-recurrence rates of our report is not better than previous reports with shorter treatment periods, intravesical MMC and THP instillation for 5 years is not beneficial to the patients with superficial bladder cancer.
Kobayashi
Shuichiro
S
Depertment of Urology, Kanto Central Hospital.
Oka
Kaoru
K
Machida
Tatsuya
T
Ishizaka
Kazuhiro
K
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D019072:Antibiotic Prophylaxis; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control* / Q000601:surgery
D016685:Mitomycin; D004317:Doxorubicin; C027260:pirarubicin